Chevron offers long-term income potential through buybacks, dividends, and global energy exposure. Colgate-Palmolive provides consistency with a diverse brand portfolio and decades of dividend increases. Merck combines near-term cash flow from Keytruda with an oncology pipeline for sustained growth. Large-cap leaders with strong brands and balance sheets benefit from patient investors. Chevron, an energy stock, has a history of buybacks and a growing dividend. Colgate-Palmolive has stable demand and a history of dividend increases. Merck’s stock has seen fluctuations due to Keytruda’s revenue reliance. Merck’s pipeline and potential new drug approvals could offset future revenue gaps.

Read more at Yahoo Finance: 3 “Forever Stocks” to Hold When the Market Won’t Sit Still